Form 8-K 1.6.15 Press Release   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 6, 2015

(Date of earliest event reported)

LABORATORY CORPORATION OF

AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

[DATA_TABLE_REMOVED]

[DATA_TABLE_REMOVED]

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On January 6, 2015, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced that that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s presentation is planned for Tuesday, January 13, 2015 at 2:00 p.m. (PST). 

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. 

Exhibits

99.1Press Release dated January 6, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

 By: /s/ F. SAMUEL EBERTS III

   F. Samuel Eberts III

   Chief Legal Officer and Secretary

January 6, 2015